|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu SL, Friess H, Kleeff J, Ji ZL and
Buchler MW: Surgical approaches for resection of pancreatic cancer:
An overview. Hepatobiliary Pancreat Dis Int. 1:118–125.
2002.PubMed/NCBI
|
|
4
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garcea G, Dennison AR, Steward WP and
Berry DP: Role of inflammation in pancreatic carcinogenesis and the
implications for future therapy. Pancreatology. 5:514–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hausmann S, Kong B, Michalski C, Erkan M
and Friess H: The role of inflammation in pancreatic cancer. Adv
Exp Med Biol. 816:129–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gukovsky I, Li N, Todoric J, Gukovskaya A
and Karin M: Inflammation, autophagy, and obesity: Common features
in the pathogenesis of pancreatitis and pancreatic cancer.
Gastroenterology. 144(1199–1209): e11942013.
|
|
8
|
Lippitz BE: Cytokine patterns in patients
with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwartz V, Lue H, Kraemer S, Korbiel J,
Krohn R, Ohl K, Bucala R, Weber C and Bernhagen J: A functional
heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett.
583:2749–2757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leng L, Metz CN, Fang Y, Xu J, Donnelly S,
Baugh J, Delohery T, Chen Y, Mitchell RA and Bucala R: MIF signal
transduction initiated by binding to CD74. J Exp Med.
197:1467–1476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Denz A, Pilarsky C, Muth D, Ruckert F,
Saeger HD and Grutzmann R: Inhibition of MIF leads to cell cycle
arrest and apoptosis in pancreatic cancer cells. J Surg Res.
160:29–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo D, Guo J, Yao J, Jiang K, Hu J, Wang
B, Liu H, Lin L, Sun W and Jiang X: D-dopachrome tautomerase is
over-expressed in pancreatic ductal adenocarcinoma and acts
cooperatively with macrophage migration inhibitory factor to
promote cancer growth. Int J Cancer. 139:2056–2067. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang S, He P, Wang J, Schetter A, Tang W,
Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, et al: A
novel MIF signaling pathway drives the malignant character of
pancreatic cancer by targeting NR3C2. Cancer Res. 76:3838–3850.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Funamizu N, Hu C, Lacy C, Schetter A,
Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, et al:
Macrophage migration inhibitory factor induces epithelial to
mesenchymal transition, enhances tumor aggressiveness and predicts
clinical outcome in resected pancreatic ductal adenocarcinoma. Int
J Cancer. 132:785–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klöppel G, Hruban RH DS, Longnecker DS,
Adler G, Kern SE and Partanen TJ: Ductal adenocarcinoma of the
pancreasPathology and Genetics of Tumours of the Digestive System.
Hamilton SR and Aaltonen LA: International Agency for Research on
Cancer Press; Lyon, France: pp. 221–230. 2000
|
|
16
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan L, Ye X, Zhou Y, Yu M, Fu Z, Chen R,
Zhuang B, Zeng B, Ye H, Gao W, et al: Macrophage migration
inhibitory factor is overexpressed in pancreatic cancer tissues and
impairs insulin secretion function of β-cell. J Transl Med.
12:922014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lauring J, Park BH and Wolff AC: The
phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target
in breast cancer. J Natl Compr Canc Netw. 11:670–678. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cohen P and Frame S: The renaissance of
GSK3. Nat Rev Mol Cell Biol. 2:769–776. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Ben QW, Yao WY, Zhang JJ, Chen DF,
He XY, Li L and Yuan YZ: BMP2 induces PANC-1 cell invasion by MMP-2
overexpression through ROS and ERK. Front Biosci. 17:2541–2549.
2012. View Article : Google Scholar
|
|
22
|
Dong QZ, Wang Y, Tang ZP, Fu L, Li QC,
Wang ED and Wang EH: Derlin-1 is overexpressed in non-small cell
lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated
up-regulation of MMP-2 and MMP-9. Am J Pathol. 182:954–964. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Costa-Silva B, Aiello NM, Ocean AJ, Singh
S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et
al: Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 17:816–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Richard V, Kindt N, Decaestecker C, Gabius
HJ, Laurent G, Noel JC and Saussez S: Involvement of macrophage
migration inhibitory factor and its receptor (CD74) in human breast
cancer. Oncol Rep. 32:523–529. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oliveira CS, de Bock CE, Molloy TJ,
Sadeqzadeh E, Geng XY, Hersey P, Zhang XD and Thorne RF: Macrophage
migration inhibitory factor engages PI3K/Akt signalling and is a
prognostic factor in metastatic melanoma. BMC Cancer. 14:6302014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang XH, Jian WH, Wu ZF, Zhao J, Wang H,
Li W and Xia JT: Small interfering RNA (siRNA)-mediated knockdown
of macrophage migration inhibitory factor (MIF) suppressed cyclin
D1 expression and hepatocellular carcinoma cell proliferation.
Oncotarget. 5:5570–5580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C, Zhou X, Li W, Li M, Tu T, Ba X, Wu
Y, Huang Z, Fan G, Zhou G, et al: Macrophage migration inhibitory
factor promotes osteosarcoma growth and lung metastasis through
activating the RAS/MAPK pathway. Cancer Lett. 403:271–279. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bifulco C, McDaniel K, Leng L and Bucala
R: Tumor growth-promoting properties of macrophage migration
inhibitory factor. Curr Pharm Des. 14:3790–3801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lue H, Thiele M, Franz J, Dahl E,
Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B and
Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes
cell survival by activation of the Akt pathway and role for
CSN5/JAB1 in the control of autocrine MIF activity. Oncogene.
26:5046–5059. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Candido J and Hagemann T: Cancer-related
inflammation. J Clin Immunol. 1 Suppl 33:S79–S84. 2013. View Article : Google Scholar
|
|
31
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bienvenu F, Jirawatnotai S, Elias JE,
Meyer CA, Mizeracka K, Marson A, Frampton GM, Cole MF, Odom DT,
Odajima J, et al: Transcriptional role of cyclin D1 in development
revealed by a genetic-proteomic screen. Nature. 463:374–378. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Drobnjak M, Osman I, Scher HI, Fazzari M
and Cordon-Cardo C: Overexpression of cyclin D1 is associated with
metastatic prostate cancer to bone. Clin Cancer Res. 6:1891–1895.
2000.PubMed/NCBI
|
|
35
|
Huang H, Hu YD, Li N and Zhu Y: Inhibition
of tumor growth and metastasis by non-small cell lung cancer cells
transfected with cyclin D1-targeted siRNA. Oligonucleotides.
19:151–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L,
Lisanti MP, Katiyar S and Pestell RG: Cyclin D1 induction of
cellular migration requires p27KIP1. Cancer Res.
66:9986–9994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong
AA, Dye C, Yang J, Dai M, Ju X, et al: Cyclin D1 regulates cellular
migration through the inhibition of thrombospondin 1 and ROCK
signaling. Mol Cell Biol. 26:4240–4256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fuste NP, Fernandez-Hernandez R, Cemeli T,
Mirantes C, Pedraza N, Rafel M, Torres-Rosell J, Colomina N,
Ferrezuelo F, Dolcet X, et al: Cytoplasmic cyclin D1 regulates cell
invasion and metastasis through the phosphorylation of paxillin.
Nat Commun. 7:115812016. View Article : Google Scholar : PubMed/NCBI
|
